Q2 2026 Natera Inc Earnings Call Transcript
Key Points
- Record-breaking test volumes with over 1,044,000 tests processed in Q2 2026, including a 56% year-over-year increase in clinical MRD units.
- Signatera achieved significant regulatory milestones, including FDA approval as a companion diagnostic and Japanese PMDA approval, enhancing its market position.
- Strong revenue growth of approximately 38% year-over-year, with revenue guidance raised by $100 million at the midpoint.
- Gross margins improved to approximately 65%, driven by ASP gains and operational efficiencies, with a long-term target of 70%+.
- Positive cash flow generation and reduced operating losses, supported by improved DSOs and effective revenue cycle management.
- Launch of enhanced Panorama test addresses low fetal fraction gap, leading to new account wins and strong women's health growth.
- Expansion of Medicare coverage for organ transplant surveillance, expected to drive Prospera ASP and volume improvements.
- Robust clinical evidence pipeline with over 70 prospective studies, positioning Natera for future guideline and reimbursement catalysts.
- NCCN Category 1 recommendation for Signatera in bladder cancer, driving adoption and commercial payer coverage.
- Early cancer detection program progressing on track with FIND study nearing full enrollment, presenting a significant future growth opportunity.
- Q2 Signatera volume growth was exaggerated by weather-related suppression in Q1, making sequential comparisons less reliable.
- Signatera ASPs remain below long-term targets, with meaningful improvement expected only in 2027 from MolDX coverage and guideline updates.
- COGS increased due to new product launches (Fetal Focus, LATITUDE, Signatera Genome) that are not yet optimized for cost efficiency.
- R&D spending is elevated, particularly for early cancer detection, which currently provides no top-line or margin benefits.
- SG&A expenses may exceed guidance due to noncash stock-based compensation and litigation costs.
- Revenue true-ups, while declining, still represent a significant portion of revenue and add volatility to financial results.
- Competition in the MRD market is increasing, though Natera believes its scale and evidence provide a competitive moat.
- The company does not expect to repeat the record sequential volume growth in Q3, indicating potential for slower growth.
- Japan launch is pending pricing and reimbursement determination, with commercial ramp expected only later this year.
- Gross margin improvement was modest sequentially, with new product mix offsetting ASP gains.
Hello, everyone. Thank you for joining us, and welcome to Natera's second quarter 2026 earnings conference call. (Operator Instructions)
I will now hand the conference over to Michael Brophy, Chief Financial Officer. Michael, please go ahead.
Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our second quarter of 2026. On the line, I'm joined by Steve Chapman, our CEO; Solomon Moshkevich, President, Clinical Diagnostics; and Alexey Aleshin, General Manager of Oncology and our Chief Medical Officer. Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR site as soon as it's available.
Starting on slide 2. During the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance, such as our operational and financial outlook
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
